BTEK:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (GBP)

ETF | Others |

Last Closing

USD 4.775

Change

-0.05 (-1.02)%

Market Cap

USD 0.49B

Volume

7.16K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R15:LSE SoftBank Group Corp.

+122.01 (+1.57%)

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

+71.00 (+0.93%)

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+4.95 (+0.57%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.06 (+0.46%)

USD 617.54B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.03 (+0.15%)

USD 617.54B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

-7.25 (-0.36%)

USD 348.03B
0QZK:LSE Coca-Cola Co.

+0.70 (+1.15%)

USD 266.08B
0QZO:LSE 0QZO

-1.40 (-1.24%)

USD 258.54B

ETFs Containing BTEK:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.53% 18% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.53% 17% F 30% F
Trailing 12 Months  
Capital Gain -2.65% 20% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.65% 18% F 37% F
Trailing 5 Years  
Capital Gain 34.37% 58% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.37% 56% F 65% D
Average Annual (5 Year Horizon)  
Capital Gain 108.85% 94% A 95% A
Dividend Return 108.85% 93% A 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 1,225.62% 5% F 4% F
Risk Adjusted Return 8.88% 37% F 50% F
Market Capitalization 0.49B 70% C- 60% D-

Annual Financials (GBP)

Quarterly Financials (GBP)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.